NuMe Health receives funds under series A-1 financing round
NuMe Health, a developer of novel, evidence-based prebiotic products, has received $675,000 from BVM Capital under series A-1 financing round.
The funds are expected to be used for product development and for commercializing the company's prebiotic products for the dietary supplement and health food markets.
Prebiotics are non-digestible ingredients that serve as nutrients for beneficial GI bacteria.
Additionally, the company has also named Dean Stull as the new CEO.
Most recently, Stull worked as the founder and principal of Innovation Science, which provides consulting services for biotechnology, medical food and functional food companies.
CommentsPost a comment
Comments may be moderated for spam, obscenities or defamation.
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs